Trials / Recruiting
RecruitingNCT06510283
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Beijing Tongren Hospital · Academic / Other
- Sex
- All
- Age
- 14 Years
- Healthy volunteers
- Not accepted
Summary
The main objective is to explore the efficacy and safety of Telitacicept in the treatment of refractory/recurrent anti-NMDAR and anti-LGI1 encephalitis. Through this prospective, single-center, open-label clinical trial, we aim to investigate the effectiveness and safety of Telitacicept in refractory/recurrent anti-NMDAR and anti-LGI1 encephalitis by add-on therapy of Telitacicept combined with traditional treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Taitacept | Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for at least 24 weeks. |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2027-07-01
- Completion
- 2028-07-01
- First posted
- 2024-07-19
- Last updated
- 2024-11-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06510283. Inclusion in this directory is not an endorsement.